Try our Advanced Search for more refined results
Life Sciences - June, 2024
259 articles
- Chevron's End Is Just The Start For Energized Agency Foes
- Will 'Moral Victory' In Purdue Ruling Help Plaintiffs?
- CUNY Medical Prof Accused Of Fabricating NIH Grant Apps
- In Chevron Case, Justices Trade One Unknown For Another
- Health Regulators Likely To Tread Carefully Post-Chevron
- Shkreli Asks High Court To Toss $64M Disgorgement Order
- Rite Aid Ch. 11 Plan OK'd With Insurers' Objections Resolved
- Philips Gets OK For $25M Med Monitoring Deal In CPAP MDL
- Nationwide Cert. Rejected In Suit Over Stolen Curaleaf Tips
- Judge Finalizes $4M Deal In Eye Doc Ransomware Dispute
- 4 Things To Know As New SPAC Rules Take Effect
- Nixed Purdue Ch. 11 Plan May Leave States Ready For A Fight
- How Cannabis Rescheduling May Affect Current Operators
- Skiing And Surfing Make Me A Better Lawyer
- Supreme Court Strikes Down Chevron Deference
- 4 Firms Guide Pair Of IPOs Totaling $457M
- Biden, Trump Spar On Abortion Access In The Wake Of Dobbs
- OptumRx Agrees To Pay $20M To Resolve DOJ Opioid Claims
- State AGs Want Stay Lifted In Generic Drug Pricing Suit
- Judge Blasts Prisons Bureau, Sends Exec To Halfway House
- Insurers Call Rite Aid Ch. 11 Opioid Deal Unfair
- Rape Kit Co. Wants Wash. Ban Lifted During Free Speech Suit
- Fed. Circ. Backs Ax Of United Therapeutics' Drug Patent
- Titanic Purdue Ruling Shifts The Balance Of Power In Ch. 11
- EU High Court Upends Servier Decrease Of Pay-For-Delay Fine
- Ex-Exec Fights Sotera's Bid To Toss Del. Stock Vesting Suit
- Judge OKs $10M Deal In Generic Price-Fixing MDL
- AbbVie Buys Bowel Disease Biotech Celsius For $250M
- Calif. Justices Say Patient's Choice A Factor In Product Cases
- Class Actions At The Circuit Courts: June Lessons
- Tracking Implementation Of IRA Programs As Election Nears
- Poor Governance Tanked Genomic Co.'s Stock, Investor Says
- Unpacking The Circuit Split Over A Federal Atty Fee Rule
- Honeywell Says Sourcing Co. Backpedaled On Supply Deal
- Del. Bankruptcy Ruling Will Give D&O Insureds Nightmares
- Justices Nix 3rd-Party Liability Releases In Purdue Ch. 11 Plan
- Ex-Outcome CEO Gets 7½ Years For Fraud Conviction
- Biotech Co. Allowed To Appeal Red Cross Antitrust Immunity
- Conn. Zantac Ruling To Include Sanofi As Settlement Looms
- Justices Leave Blurry Line In Place On Misinformation Fight
- Moms For America Sues Biden Admin Over Vax Liability Law
- Design Patent Attys Wary Of Applicant Disclosure Proposal
- Justices Chide 5th Circ. In Biden Social Media Case
- Ga. High Court Told To Skip Inventor's 'Clerical Mistake' Fight
- State Data Privacy Law Patchwork: Midyear Report
- Choctaw Nation Wants 9th Circ. Rehearing In CVS Arb. Dispute
- Apple Watch Improvement Is 'Inferior,' Docs Tell 9th Circ.
- House GOP Gears Up For The End Of Chevron Deference
- Squire Patton Adds Epstein Becker Healthcare Atty In DC
- Pharma Co. PhaseBio Can Exit Ch. 11 With Wind-Down Plan
- No Matter The Purdue Ruling, Mass Tort Reform Is Needed
- High Court 'Inadvertently' Posts Order Punting Abortion Case
- High Court Axes Challenge To Biden Admin's Social Media Work
- Riley Safer Expands IP Practice With Chicago Partner
- PTAB Wipes Out UMass Skin Disease Treatment Patent
- Fed. Circ. Restores Amarin's Skinny Label Suit Against Hikma
- Sarissa Capital, Founder Settle Bioverativ Suit In Del. For $40M
- Indiana U Settles Ricin-Carrying Fruit Fly Export Violations
- Plaintiffs Firms Appealing $2.1B Fee Order In Opioid Case
- Chancery OKs $71M Premier Deal, $14M Four-Firm Fee
- UK Billionaire's Pilot Avoids Prison For Insider Trading
- Lye Buyers Can't Get Court OK For $38.5M Antitrust Deals
- After A Brief Hiccup, The 'Rocket Docket' Soars Back To No. 1
- Litigation Pro Rejoins GRSM50 In Calif. From DeHay & Elliston
- Judge Mulls BioXcel's Duty To Tell Investors Of FDA Troubles
- Alleged Contract Killing Sparks Delaware Chancery Lawsuit
- NYC Pharmacy Owners Get Jail Time For $18M Med Fraud
- Justices Undo Terror Victims' Win, Citing Twitter Decision
- LA Schools Says Pseudoscience Infected 9th Circ. Vax Ruling
- Protecting Trade Secrets In US, EU Gov't Agency Submissions
- Ark. AG Sues Pharmacy Benefit Managers Over Opioids
- Suit Over Medical Screws Filed Too Late, Texas Panel Finds
- Jurisdictional Discovery Ordered In NJ COVID Test Fraud Suit
- Catching Up With Delaware's Chancery Court
- Justices Pass On Conn. School Vaccine Mandate Fight
- Cooley-Led Therapy Developer Alumis Aims For $300M IPO
- Altria Subsidiary Allowed To Sell Menthol-Flavored Vapes
- Recruitment Trends In Emerging Law Firm Frontiers
- Biotech Co. Hits Ch. 11 With Plans For Sale And 'Reboot'
- Justices Pass On Rutgers COVID-19 Vax Mandate Case
- Drug Cos., IP Attys Back Cellect In High Court Efforts
- Drugmakers Decline To Drop Patent Listings After FTC Letters
- After Fed. Circ. Win, Bausch Sues Alvogen Over Drug Patents
- Pay-For-Delay Drug Case Not Time-Barred, UK Tribunal Says
- Ex-CEO Found Liable For $1 Now Seeks Atty Fees For Del. Suit
- Costco Sued Over PFAS In Kirkland Brand Baby Wipes
- 8 Firms To Lead 4 IPOs Totaling $806M As Action Heats Up
- 4 Tips For Drafting Earnouts To Avoid Disputes
- Taxation With Representation: Travers Smith, Potamitis Vekris
- Glassblowing Makes Me A Better Lawyer
- Ex-DEA Heads Echo GOP AGs' Call For Pot Rescheduling Hearing
- Patent Owners, Challengers Spar Over PTAB Rule Proposal
- Eli Lilly Launches Round Of Diabetes Drug Suits
- Spinal Implant Maker Can Liquidate Under Ch. 11 Plan
- 11th Circ. Upholds $2.5M Pelvic Mesh Verdict, Rules Suit Timely
- No Access To Ethics Docs For Ex-NJ Official Yet, Judge Rules
- No Atty, No Case: Judge Tosses Attack On Psychedelics Ban
- HHS Drug Pricing Program Flouts Constitution, Boehringer Says
- 11th Circ. Nixes J&J Sunscreen Benzene MDL Settlement
- Theravance, Mylan Say Chinese Co. Copied COPD Drug
- USPTO's AI-Assisted Inventions Guidance Irks ABA IP Section
- 11th Circ. Backs Stryker's Defeat Of Fired Worker's Leave Suit
- Flawed Fintiv Rule Should Be Deemed Overreach In Tech Suit
- How Associates Can Build A Professional Image
- High Court Petition Asks Justices: What's A 'Willful' Kickback?
- Company, States Battle In Court Over At-Home Rape Kits
- CORRECTED: Drug Cos., PBMs Score Win In Calif. AG's Insulin Price Suit
- Fla. Immune To Contract Suit Over COVID Tests, 4th Circ. Says
- 11th Circ. Orders New Shrimp Secrets Trial Over Judge's Exit
- High Court's Abortion Pill Ruling Shuts Out Future Challenges
- COVID Test Maker Can't Shake All Of $30M Faulty Kit Suit
- J&J Fights Law Firm's Bid To Nix Subpoenas In Talc Brawl
- Emerging Trends In ESG-Focused Securities Litigation
- Restitution Plan For Lead-Test Defects Leaves Judge Uneasy
- Orange Book Warnings Highlight FTC's Drug Price Focus
- Latham Leads Boston Scientific On $1.16B Silk Road Deal
- Firms Must Rethink How They Train New Lawyers In AI Age
- A Plaintiffs-Side Approach To Cochlear Implant Cases
- Cancer Test Company DermTech Hits Ch. 11, Seeking Sale
- Samsung Bioepis Denies Infringing Blood Treatment Patent
- Teva, DOJ Signal Key Kickback Case May Fizzle At 1st Circ.
- NJ Firm Defends Lien On Ex-Client's Patents After Unpaid Bills
- USC Allegedly Used 'Junk Science' On Black Kidney Patients
- Mifepristone Ruling Means End Of Texas DACA Suit, Feds Say
- DOJ Wants 15 Years For Outcome CEO's $1B Fraud
- Top Patent Eligibility Rulings In The Decade Since Alice
- Ex-Stimwave CEO Gets 6 Years For Dummy Implant Scheme
- HUD Freed From Pa. Pot Patients' Suit Over Housing Rebuff
- Drugmaker, PE Investor Sued In Del. Over 'Unfair' Deal Terms
- Zantac Suits Must Exit State Court, Conn. Judge Told
- Fed. Circ. Says Errors Led To Injunction In Trade Secrets Suit
- Catching Up With Delaware's Chancery Court
- Talc Claimants Want Documents In Fight Over J&J Unit Venue
- Think Like A Lawyer: Always Be Closing
- Justices Are Asked To Wade Into Blood Pressure Drug IP Fight
- Janssen Hit With $150M Verdict In HIV Drug False Claims Suit
- 3rd Circ. Merges 3 Challenges To Medicare Drug Price Talks
- Judge Won't Undo Save Of J&J Patent After Fed. Circ. Ruling
- Tracking China's Push To Invalidate Foreign Patents
- Pfizer Worker's Ex-Wife Can't Raid 401(k) To Collect Damages
- Australian Biotech Firm Telix Pharmaceuticals Pulls US IPO
- Biotech Clinches Latest Funding Round With $55M In Tow
- Takeaways From Nat'l Security Division's Historic Declination
- IP Forecast: Cooley Atty Faces DQ Bid Over Past Patent Work
- Justices Hand Abortion Advocates An Incomplete Win
- Cooley-Led Diagnostics Firm Tempus AI Raises $411M IPO
- Thomas Targets Group Standing In Mifepristone Ruling
- Full Fed. Circ. Rejects Rehearing Bids In Xifaxan Case
- Feds' Forfeiture Error Won't Tank Outcome Execs' Conviction
- Cannabis Cos. Make Deal Ahead Of Expected DEA Downgrade
- North Carolina Lawmakers Mull Outlawing 'Gas Station Heroin'
- Teva Wins Pause Of Order Ousting Patents From Orange Book
- CVS Dodges Discovery Audit In Generic Drug Collusion Suit
- GOP Lawmakers Want China Patent Data Amid Tech Pact Talks
- Vero Biotech Tried To 'String Along' Safety Monitor, Suit Says
- EU Makes First Ever Formal Pharma Price-Fixing Complaint
- JP Morgan Closes Debut Life Sciences Fund At Over $500M
- Playing Chess Makes Me A Better Lawyer
- Abortion Medication Case Ends 'With A Whimper' At High Court
- Tillis Told Drug Patents Are Too Complex For Easy Answers
- Lies At Heart Of Fraud Case Over COVID Test Kits, Jurors Told
- 2nd Circ. Backs Brokerage In Suit Over Biotech's Failed IPO
- Lipitor Buyers Get Final OK For $93M Deal In Antitrust Fight
- SPAC Dealmakers Expect Modest Pickup After Market Bottom
- Directors Of Defunct Med Tech SPAC Seek Toss Of Del. Suit
- Forte Biosciences Reaches $2M Deal To End Chancery Suit
- 'Natural' Toothpaste Brand Loaded With PFAS, Moms Say
- 32 AGs Urge Justices Take Up Okla. PBM Law Fight
- Litigation Inspiration: Attys Can Be Heroic Like Olympians
- Martin Shkreli Told To Defend Use Of Wu-Tang Album
- Pharmacy Co. Optio Gets Interim OK For $10M DIP Package
- Fed. Circ. Reinstates Parts Of Blood Analyzer Secrets Verdict
- 9th Circ. Judge On Theranos Appeal: 'Good Story' For Holmes
- AI No Scarier Than Nail Guns Or Microscopes, Kappos Says
- NJ Supreme Court Rejects Bid For Roundup Mass Tort
- Slow IPO Recovery Expected To Accelerate In 2025
- Updated Federal Rules Can Improve Product Liability MDLs
- 10 Firms Seek $13M Fee For Effexor Antitrust Deal
- Lean Into The 'Great Restoration' To Retain Legal Talent
- WilmerHale Lands Latham Atty To Help Lead Life Sciences
- FDA Urges 11th Circ. To Back E-Cig Ban Over High Nicotine
- 5 Teva Inhaler Patents Kicked Out Of Orange Book
- Bankrupt UpHealth Warned Of Criminal Charges In India
- DOJ, FDA Form Task Force To Crack Down On Illegal E-Cigs
- Baltimore Lands $45M Deal With Allergan In Opioid Litigation
- 9th Circ. Says Choctaw's Dispute With CVS Must Be Arbitrated
- Colo. Justices Say Toxic Tort Plaintiffs Didn't Waive Privilege
- Drugmakers Look To Nix Non-Insulin Claims From AG Suit
- Parexel Says Staffing Firm Liable For Temp's Alleged Fraud
- Juul Ends FOIA Suit Over FDA E-Cig Decisions
- How Cannabis Rescheduling May Alter Paraphernalia Imports
- What The NYSE Proposed Delisting Rule Could Mean For Cos.
- 9th Circ. To Hear Args In Psilocybin Right-To-Try Case
- Catching Up With Delaware's Chancery Court
- Ventilator Co. Vyaire Hits Ch. 11 As COVID Demand Wanes
- Pharmacy Biz Files Ch. 11 With More Than $235M In Debt
- Motley Rice Allocated Biggest Share Of $2B Opioid Fees
- Talc User With Cancer Had 2nd Exposure Path, Jury Hears
- Ozempic MDL Gets New Judge After Judge Pratter's Death
- Split 9th Circ. Revives LA Schools Vaccine Policy Row
- Chicago-Area Man Charged With $60M COVID Test Fraud
- Conn. Judge Pushes State For Proof In $11M Kickback Case
- DC Circ. Undoes Library Of Congress Win In Fair Use Fight
- SEC Fines Ex-AstraZeneca Insider $1.4M For Merger Trades
- Ranbaxy Units Overcome Lipitor Antitrust MDL
- Goodwin, Cooley Lead J&J-Backed Neurological Firm's IPO
- COVID Test Supplier Sees $1.4M Default Loss In Gopuff Suit
- Acorda Therapeutics Gets OK On $185M Ch. 11 Sale To Merz
- Fed. Circ. Panel Doubts Bid To Nix Actavis' $12M Deduction
- White Collar Boutique Sued By Ex-Client Over Representation
- USPTO Rejects Apple's Bids To Reexamine Masimo Patents
- Drugmakers Escape Cancer Drug Antitrust Claims For Now
- Pharma Co. Misled Investors On Seizure Drug Trial, Suit Says
- 8th Circ. Affirms Cigna Noncompete Applies To CVS Hire
- $25 Million Flint Water Class Deal Gets Early OK
- Judge OKs $42M Stent IP Verdict, Discards Willfulness Finding
- FDA Warning Indicates Scrutiny Of Regenerative Health Cos.
- 2 Regulatory Approaches To Psychedelic Clinical Trials
- FDA Urges High Court To Hear 5th Circ. Flavored E-Cig Case
- Bankruptcy Judges Can Justly Resolve Mass Tort Cases
- Abbott Labs Must Face Bulk Of Glucerna False Ad Suit
- Biote Investors Sue Cooley, SPAC After Huge Merger Loss
- Law Firm Says Axe 'Draconian' J&J Subpoena In Talc Claim
- 'Brussels Effect' Of EU's AI Act Is Uncertain, Legal Pros Say
- Fishing Makes Me A Better Lawyer
- Pharma Co. Should Get Hungarian Rebate, ECJ Adviser Says
- USPTO Fee Hike Finds Ally In Google, But Others Have Gripes
- AI Co., Biotech Prep IPOs Worth $602M As Novelis Delays
- Medtronic Can't Pause FCA Claims For 1st Circ. Detour
- McDermott Lands King & Spalding White Collar Pro In Atlanta
- A Healthier Legal Industry Starts With Emotional Intelligence
- Pinsent Mason Guides Lab Services Biz On £11M Fundraise
- AstraZeneca Completes $2.4B Deal To Buy Pharma Co. Fusion
- Judiciary Panel Clears 1st MDL Rule, Eyes 'Mouthpiece' Amici
- Insulin Pens Exposed Patients To Disease, Hospital Says
- Biotech RenovaCare Can't Beat Investors' Stock Promo Suit
- Chinese Fund Asks To Nix Doc Bid In $830M Transaction Row
- FDA Advisers Rebuff Bid To Treat PTSD With MDMA
- Zantac Suits Belong In Conn. State Court, Cancer Patients Say
- Pharma Cos. Tell Justices Feds Support Remanding Terror Suit
- J&J Owes $260M To Ore. Talc Mesothelioma Patient, Jury Says
- Honeywell Manager 'Dismissive' Of Black Employee, Suit Says
- To Make Your Legal Writing Clear, Emulate A Master Chef
- Circuit Judge Writes An Opinion, AI Helps: What Now?
- Illumina Board Puts Grail Spinoff In Motion After EU OK
- Fed. Circ. Rulings Crystallize Polymorph Patent 'Obviousness'
- DC Circ. Ruling Heightens HHS Contract Pharmacy Challenges
- Research Co. Pays Record $35M Fine In Dog Abuse Case
- Ex-Biopharma Co. Prez Accused Of Defecting With Secrets
- Justices Won't Review Contempt Sanctions Against Drug Co.
- Glycine Co. Couldn't Compel Cooperation, Trade Court Told
- Drug Cos. Can Depose DC AG In Drug Price-Fixing Row
- 3 Infringement Defenses To Consider 10 Years Post-Nautilus
- Group Defends Plan For PED-Fueled Athletic Competitions
- Ex-SoftBank GC Joins Foley & Lardner As Partner In SF
- Biotech Firm, Mobile App Prepare To Enter IPO Fray
- House COVID Panel Questions Fauci Over Pandemic Origins
- Ropes & Gray Guides Becton On $4.2B Edwards Unit Buy
- Blockbuster Summer: 10 Big Issues Justices Still Must Decide